Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 494, Issue 1, Pages 537-551Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2015.08.038
Keywords
Mucoadhesive films; Buccal films; Sublingual films; Opioid dependence; Pain; Migraines
Categories
Funding
- FCT grant [SFRH/BDE/52.098/2013]
- QREN SI-I&DT Empresa Individual Project [38480]
Ask authors/readers for more resources
Oral drug delivery is the most common route of drug administration. Nevertheless, there are some important limitations that reinforce the need for developing new drug delivery systems. Mucoadhesive oral films (MOF) are promising dosage forms that adhere to the oral mucosa and deliver the drug through it, which present several advantages. These include: bypassing the hepatic first pass effect, fast onset of action, ease of transportation and handling. The use of such dosage form is beneficial for drugs that have poor oral bioavailability and also for drugs that need to be rapidly absorbed. In spite of the known benefits, the number of marketed MOF is still quite small. This review explores the products under development and corresponding clinical trials in respect to their status, therapeutic indication, companies involved and technologies. In this way, it was possible to identify the preferred therapeutic indications, new research and market trends as well as future prospects of MOF. Moreover, it is reasonable to expect an increase in the number of products on the market due to their great potential to satisfy unmet medical needs. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available